These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38881076)

  • 41. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis.
    Jingfan Z; Ling L; Cong L; Ping L; Yu C
    Arch Endocrinol Metab; 2019; 63(5):478-486. PubMed ID: 31271575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Iijima H; Kifuji T; Maruyama N; Inagaki N
    Adv Ther; 2015 Aug; 32(8):768-82. PubMed ID: 26280756
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials.
    Blonde L; Woo V; Mathieu C; Yee J; Vijapurkar U; Canovatchel W; Meininger G
    Curr Med Res Opin; 2015 Nov; 31(11):1993-2000. PubMed ID: 26373629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
    Devineni D; Polidori D
    Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
    Wilding JP; Charpentier G; Hollander P; González-Gálvez G; Mathieu C; Vercruysse F; Usiskin K; Law G; Black S; Canovatchel W; Meininger G
    Int J Clin Pract; 2013 Dec; 67(12):1267-82. PubMed ID: 24118688
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
    Ren DY; Zhang Y
    Curr Drug Targets; 2018; 19(9):1051-1057. PubMed ID: 29848274
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
    Powell J; Miller SA; Taylor JR
    South Med J; 2015 Feb; 108(2):82-90. PubMed ID: 25688892
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
    Seufert J
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S65-9. PubMed ID: 24481635
    [No Abstract]   [Full Text] [Related]  

  • 50. When Guidelines Fail: Euglycemic Diabetic Ketoacidosis After Bariatric Surgery in a Patient Taking a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report.
    Lane S; Paskar D; Hamed S; Goffi A
    A A Pract; 2018 Jul; 11(2):46-48. PubMed ID: 29634546
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
    Johnston R; Uthman O; Cummins E; Clar C; Royle P; Colquitt J; Tan BK; Clegg A; Shantikumar S; Court R; O'Hare JP; McGrane D; Holt T; Waugh N
    Health Technol Assess; 2017 Jan; 21(2):1-218. PubMed ID: 28105986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
    Shyangdan DS; Uthman OA; Waugh N
    BMJ Open; 2016 Feb; 6(2):e009417. PubMed ID: 26911584
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [XIGDUO - fixed combination of the active ingredients dapagliflozin and metformin].
    Edelsberger T
    Vnitr Lek; 2016 Mar; 62(3):199-201. PubMed ID: 27180669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.
    Fulcher G; Matthews DR; Perkovic V; de Zeeuw D; Mahaffey KW; Mathieu C; Woo V; Wysham C; Capuano G; Desai M; Shaw W; Vercruysse F; Meininger G; Neal B;
    Diabetes Obes Metab; 2016 Jan; 18(1):82-91. PubMed ID: 26450639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
    Sabapathy S; Neslusan C; Yoong K; Teschemaker A; Johansen P; Willis M
    J Popul Ther Clin Pharmacol; 2016; 23(2):e151-68. PubMed ID: 27463416
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
    Leiter LA; Yoon KH; Arias P; Langslet G; Xie J; Balis DA; Millington D; Vercruysse F; Canovatchel W; Meininger G
    Diabetes Care; 2015 Mar; 38(3):355-64. PubMed ID: 25205142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
    Tahrani AA
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):678-9. PubMed ID: 24948512
    [No Abstract]   [Full Text] [Related]  

  • 59. The proliferation of irrational metformin fixed-dose combinations in India.
    Evans V; Pollock AM
    Lancet Diabetes Endocrinol; 2015 Feb; 3(2):98-100. PubMed ID: 25618292
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
    Sha S; Polidori D; Heise T; Natarajan J; Farrell K; Wang SS; Sica D; Rothenberg P; Plum-Mörschel L
    Diabetes Obes Metab; 2014 Nov; 16(11):1087-95. PubMed ID: 24939043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.